Skip to main content

Clinical trial KEYNOTE-756

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Cancers
Organ Breast
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Merck
EudraCT Identifier 2017-004869-27
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03725059
Inclusion criteria ER+/HER2-. Stage III. cT1c-2 (>2cm). N1-2 or T3-4N0-2. Neoadjuvant
Last update